Muhdo & University of Singapore partnership

IM Company Muhdo Partner With University Of Singapore (NUS) To Undertake The Most Advanced Research Project On Longevity

Muhdo Health is joining forces with the National University of Singapore (NUS) and Dr Brian Kennedy to bring about one the most advanced research projects focused on healthy ageing and longevity ever undertaken. The research will take place on a global scale, involving the analysis of epigenetic changes on the human body. The study will focus on the changes that occur during ageing and the effects lifestyle and environment have on gene expression.

Unlike the outdated and conventional method of measuring age with time, epigenetic ageing also known as biological age can be accelerated and reversed. Participants will be analysed while living their normal, everyday lives, through their stressors and environmental challenges with epigenetic ageing being analysed through DNA methylation.

DNA methylation has been argued to be related to all mortality in later life, however, it is thought not to be a cause of ageing but a marker that can be used to judge accelerated ageing. By utilising this important marker, it may be possible to predict many disease and lifestyle conditions before they come to pass. With the fundamental aim of decelerating the ageing process and preventing these ailments from occurring in the first place.

“Prevention is the best cure”

Muhdo has built its DNA and epigenetic offering to be accessed through a ground-breaking mobile application. This application will also be available to the participants in the study in a white label form; highlighting the technological advances in the study and information sharing of DNA analysis.

Nathan Berkley, CEO of Muhdo, said:

“We at Muhdo are very excited to be aiding NUS carry out this cutting-edge research with the custom Muhdo analysis and mobile application”. expresses the Chief Executive of Muhdo, Nathan Berkley. “DNA and epigenetics has the capability to help everyone at every stage of life to reach their full health potential. We believe this is a true milestone in the global application of epigenetics”

Sarah Singapore, NUS Spokesperson, said:

“We’re always searching for novel ways to push the boundaries of our research at NUS and epigenetics is at the pinnacle of human longevity and genetic science. Everyone involved at NUS is very excited to be able to bring our studies to fruition with the aid of Muhdo. We believe, above all else, that we will reach invaluable conclusions that will reverberate for years to come”

About Muhdo

Muhdo is the first company in the world to offer a true internal wellness epigenetic profiling programme direct to companies and consumers, inspiring and supporting people to live healthier, happier, longer lives. As a next generation genetic and big data company, its vision is the mass personalisation of preventive and curative health through epigenetics and analytics, delivering a truly holistic and objective health and wellness programme.